ESR1 and breast carcinoma: Baseline TILs in our population ranged between 0 and 50%, which is consistent with the data from Stanton et al. [24] showing that 94% of ER+ menopausal breast cancer patients had less than 49% TILs when diagnosed (n = 2410).